Michael Dougan

13.2k total citations · 2 hit papers
129 papers, 5.9k citations indexed

About

Michael Dougan is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Michael Dougan has authored 129 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 58 papers in Immunology and 21 papers in Epidemiology. Recurrent topics in Michael Dougan's work include Cancer Immunotherapy and Biomarkers (65 papers), Immunotherapy and Immune Responses (29 papers) and Immune Cell Function and Interaction (26 papers). Michael Dougan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (65 papers), Immunotherapy and Immune Responses (29 papers) and Immune Cell Function and Interaction (26 papers). Michael Dougan collaborates with scholars based in United States, United Kingdom and Argentina. Michael Dougan's co-authors include Glenn Dranoff, Stephanie K. Dougan, Hidde L. Ploegh, Jessica R. Ingram, Kai W. Wucherpfennig, Adrienne Luoma, K. Christopher García, Kerry L. Reynolds, Steven C. Almo and Novalia Pishesha and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Michael Dougan

117 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

2020 307 citations Stephanie K. Dougan, Michael Dougan et al. profile →
Immune mechanisms of toxicity from checkpoint inhibitors

2023 136 citations Stephanie K. Dougan, Michael Dougan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Dougan United States	39	3.5k	2.8k	1.3k	587	551	129	5.9k
Michel Obéid Switzerland	22	4.2k 1.2×	3.5k 1.3×	1.5k 1.2×	293 0.5×	754 1.4×	41	7.4k
Sebastian Kobold Germany	36	3.3k 0.9×	2.7k 1.0×	1.7k 1.4×	380 0.6×	207 0.4×	141	5.5k
Aitziber Buqué United States	25	3.3k 0.9×	3.2k 1.1×	1.7k 1.4×	257 0.4×	441 0.8×	51	6.2k
Karen S. Anderson United States	40	1.6k 0.5×	1.9k 0.7×	2.2k 1.8×	768 1.3×	460 0.8×	134	4.9k
Michael R. Verneris United States	54	4.1k 1.2×	6.5k 2.4×	1.5k 1.2×	382 0.7×	939 1.7×	254	10.7k
Ahmad A. Tarhini United States	46	5.6k 1.6×	3.6k 1.3×	2.4k 1.9×	357 0.6×	508 0.9×	276	8.0k
Bernard A. Fox United States	48	4.4k 1.2×	4.4k 1.6×	2.2k 1.8×	363 0.6×	533 1.0×	200	7.6k
Hassane M. Zarour United States	41	5.6k 1.6×	5.2k 1.9×	1.9k 1.5×	306 0.5×	414 0.8×	104	8.0k
Jonathan S. Serody United States	53	3.3k 0.9×	5.4k 2.0×	2.1k 1.6×	276 0.5×	490 0.9×	184	9.0k
Encouse B. Golden United States	24	2.7k 0.8×	1.7k 0.6×	855 0.7×	613 1.0×	469 0.9×	34	4.7k

Countries citing papers authored by Michael Dougan

Since Specialization

Citations

This map shows the geographic impact of Michael Dougan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Dougan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Dougan more than expected).

Fields of papers citing papers by Michael Dougan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Dougan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Dougan. The network helps show where Michael Dougan may publish in the future.

Co-authorship network of co-authors of Michael Dougan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Dougan. A scholar is included among the top collaborators of Michael Dougan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Dougan. Michael Dougan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hulsman, Marc, Katherine A. Donovan, Eric S. Fischer, et al.. (2024). SMAC mimetics induce human macrophages to phagocytose live cancer cells. PubMed. 5(1). ltaf026–ltaf026.

Dougan, Michael. (2023). Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions. Immunological Reviews. 318(1). 11–21. 3 indexed citations

Badran, Yousef R., Fangwen Zou, Sienna Durbin, et al.. (2023). Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. Journal for ImmunoTherapy of Cancer. 11(6). e007195–e007195. 17 indexed citations

Crowley, Stephanie J., Patrick T. Bruck, Max Heckler, et al.. (2023). cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity. The Journal of Immunology. 210(7). 991–1003. 7 indexed citations

Bort, Guillaume, François Lux, Agnès Hagège, et al.. (2023). AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors. Nanoscale. 16(5). 2347–2360. 7 indexed citations

Walsh, Michael J., Lestat R. Ali, Patrick J. Lenehan, et al.. (2023). Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. PubMed. 3(1). ltad011–ltad011. 13 indexed citations

Walsh, Michael J., Megan T. Hoffman, Michael Dougan, et al.. (2023). DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity. Science Advances. 9(47). 5 indexed citations

Quijano‐Rubio, Alfredo, Huilin Yang, Isabel Leung, et al.. (2022). A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nature Biotechnology. 41(4). 532–540. 49 indexed citations

Gaglione, Stephanie, Blake E. Smith, Ellen J. Kim, et al.. (2022). Antigen identification and high-throughput interaction mapping by reprogramming viral entry. Nature Methods. 19(4). 449–460. 49 indexed citations

10.

Ascierto, Paolo A., Lisa H. Butterfield, Kirk A. Campbell, et al.. (2021). Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy). Journal of Translational Medicine. 19(1). 13–13. 2 indexed citations

11.

Xie, Yushu Joy, Michael Dougan, Jessica R. Ingram, et al.. (2020). Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. Cancer Immunology Research. 8(4). 518–529. 82 indexed citations

12.

Thompson, Leah L., Ethan Katznelson, Donna Leet, et al.. (2020). Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor–induced gastroenterocolitis. European Journal of Cancer. 142. 143–146. 7 indexed citations

13.

Crowley, Stephanie J., Patrick T. Bruck, Michael J. Walsh, et al.. (2020). Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology. 10(2). 190235–190235. 11 indexed citations

14.

Schoenfeld, Sara, Mary E. Aronow, Rebecca Karp Leaf, Michael Dougan, & Kerry L. Reynolds. (2019). Diagnosis and Management of Rare Immune-Related Adverse Events. The Oncologist. 25(1). 6–14. 24 indexed citations

15.

Xie, Yushu Joy, Michael Dougan, Noor Jailkhani, et al.. (2019). Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proceedings of the National Academy of Sciences. 116(16). 7624–7631. 234 indexed citations

16.

Dougan, Michael, Jessica R. Ingram, Hee‐Jin Jeong, et al.. (2018). Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs. Cancer Immunology Research. 6(4). 389–401. 71 indexed citations

17.

Clancy‐Thompson, Eleanor, Lestat R. Ali, Patrick T. Bruck, et al.. (2017). IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunology Research. 6(1). 25–35. 24 indexed citations

18.

Tyler, Paul, Boris Klebanov, Trinayan Kashyap, et al.. (2017). Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Molecular Cancer Therapeutics. 16(3). 428–439. 28 indexed citations

19.

Dougan, Michael & Stephanie K. Dougan. (2017). Targeting Immunotherapy to the Tumor Microenvironment. Journal of Cellular Biochemistry. 118(10). 3049–3054. 46 indexed citations

20.

Jinushi, Masahisa, Yukoh Nakazaki, Michael Dougan, et al.. (2007). MFG-E8–mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. Journal of Clinical Investigation. 117(7). 1902–1913. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact